A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes ( Leng et al., Aging Dis, 11:216-228, 2020 ). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Vaccine, coronavirus, Pneumonia, aging, Infection, lung, MSCs, drug, immune system, outcome, Patient, severe pneumonia, New coronavirus, administration, MSC, Elderly patient, Safe, intravenous, stem cell, MSC therapy, acute respiratory syndrome, acute respiratory illness, therapeutic intervention, microenvironment, treating COVID-19 patients, approach, effective, caused, reported, functional, demonstrated, displaying, inhibiting, cohort of patient, endogenous repair, patients with COVID-19, the SARS-CoV-2, 【제목키워드】 COVID-19, infusion, induced, promise, show, STEM,